Regeneron Pharmaceuticals, Inc. (LON:0R2M)
511.39
-2.70 (-0.53%)
At close: Jun 20, 2025
Regeneron Pharmaceuticals Employees
Regeneron Pharmaceuticals had 15,106 employees as of December 31, 2024. The number of employees increased by 1,656 or 12.31% compared to the previous year.
Employees
15,106
Change (1Y)
1,656
Growth (1Y)
12.31%
Revenue / Employee
719.24K GBP
Profits / Employee
229.74K GBP
Market Cap
40.07B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 15,106 | 1,656 | 12.31% |
Dec 31, 2023 | 13,450 | 1,599 | 13.49% |
Dec 31, 2022 | 11,851 | 1,483 | 14.30% |
Dec 31, 2021 | 10,368 | 1,245 | 13.65% |
Dec 31, 2020 | 9,123 | 1,023 | 12.63% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 94,300 |
GSK plc | 68,629 |
Haleon | 24,561 |
Smith & Nephew | 17,349 |
ConvaTec Group | 10,489 |
Hikma Pharmaceuticals | 9,500 |
HUTCHMED (China) | 1,811 |
Genus | 3,500 |
Regeneron Pharmaceuticals News
- 3 days ago - $100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth This Much Today - Benzinga
- 4 days ago - Regeneron, Sanofi win FDA label expansion for Dupixent against rare skin disorder - Seeking Alpha
- 4 days ago - Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease - WSJ
- 4 days ago - Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP) - GlobeNewsWire
- 4 days ago - Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid - GlobeNewsWire
- 7 days ago - Regeneron is said to have declined a higher bid for 23andMe after Wojcicki's offer - Seeking Alpha
- 7 days ago - Regeneron declines to make higher bid for 23andMe after Wojcicki's $305 million offer - Reuters
- 8 days ago - 23andMe’s founder wins bid to regain control of bankrupt DNA testing firm - The Guardian